论文部分内容阅读
目的观察阿托伐他汀钙使用剂量对预防颈动脉粥样硬化脑梗死的影响。方法选取医院2013年1月-2014年11月收治的颈动脉粥样硬化脑梗死患者50例,告知患者及患者家属治疗方式后,按随机分组方式分为治疗组和对照组各25例,对照组采取阿司匹林+阿托伐他汀钙治疗,阿托伐他汀钙每天常规用药10mg;治疗组采取阿托伐他汀钙+阿司匹林治疗,阿托伐他汀钙每天常规用药20mg。比较2组临床效果。结果治疗后随访,治疗组随访期脑梗死发生率为12.00%明显低于对照组的20.00%(P<0.05)。2组治疗后颈动脉狭窄和硬化情况与治疗前比较差异有统计学意义(P<0.05);且治疗组优于对照组,差异均有统计学意义(P<0.05)。经半年随访观察2组患者的肝功异常情况差异无统计学意义(P>0.05)。结论大剂量阿托伐他汀钙治疗颈动脉粥样硬化的疗效更加确切,且无明显不良反应,值得推广与应用。
Objective To observe the effect of atorvastatin calcium on the prevention of carotid atherosclerosis cerebral infarction. Methods Fifty patients with carotid atherosclerosis cerebral infarction admitted from January 2013 to November 2014 in our hospital were divided into treatment group (25 cases) and control group (25 cases) Group taking aspirin + atorvastatin calcium treatment, atorvastatin calcium daily routine medication 10mg; treatment group to take atorvastatin calcium + aspirin treatment, atorvastatin calcium daily routine medication 20mg. The clinical effects of two groups were compared. Results After treatment, the incidence of cerebral infarction in the treatment group was significantly lower than that of the control group (12.00% vs 20.00%, P <0.05). The carotid artery stenosis and sclerosis in the two groups were significantly different from those before treatment (P <0.05). The treatment group was better than the control group, the difference was statistically significant (P <0.05). After six months of follow-up observation of two groups of patients with liver function abnormalities was no significant difference (P> 0.05). Conclusion High-dose atorvastatin calcium treatment of carotid atherosclerosis more accurate and no obvious adverse reactions, it is worth promoting and application.